Behavioral
watch and wait
watch and wait is a behavioral intervention with 5 clinical trials. Currently 4 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
BEHAVIORAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
4(80%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
2
40%
Ph not_applicable
1
20%
Ph phase_4
1
20%
Ph phase_3
1
20%
Phase Distribution
0
Early Stage
2
Mid Stage
2
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
1(20.0%)
N/ANon-phased studies
1(20.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
4
trials recruiting
Total Trials
5
all time
Status Distribution
Active(4)
Completed(1)
Detailed Status
Recruiting3
Completed1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
4
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 22 (40.0%)
Phase 31 (20.0%)
Phase 41 (20.0%)
N/A1 (20.0%)
Trials by Status
recruiting360%
completed120%
active_not_recruiting120%
Recent Activity
4 active trials
Showing 5 of 5
recruitingnot_applicable
Watch and Wait in PD-1 Monoclonal Antibody Treated dMMR/MSI-H Distal Rectal Cancer
NCT04643041
recruitingphase_2
Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer
NCT06204094
recruitingphase_4
Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)
NCT07268222
active_not_recruitingphase_2
Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT04304209
completedphase_3
Mantel Cell Lymphoma Efficacy of Rituximab Maintenance
NCT00921414
Clinical Trials (5)
Showing 5 of 5 trials
NCT04643041Not Applicable
Watch and Wait in PD-1 Monoclonal Antibody Treated dMMR/MSI-H Distal Rectal Cancer
NCT06204094Phase 2
Node-sparing Radiotherapy Combined With Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer
NCT07268222Phase 4
Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)
NCT04304209Phase 2
Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer
NCT00921414Phase 3
Mantel Cell Lymphoma Efficacy of Rituximab Maintenance
All 5 trials loaded
Drug Details
- Intervention Type
- BEHAVIORAL
- Total Trials
- 5